Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | GRK2 | P25098 | 1/20 | 0.30 |
| ▸ | GRK5 | P34947 | 1/20 | 0.30 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.30 |
| ▸ | MAP4K3 | Q8IVH8 | 2/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435972 | 0.92 | ELANE (0.32) | ELANEGRIN1GRIN2B | |
| SCHEMBL31436005 | 0.92 | MAP4K3 (0.37) | METGRK2GRK5PAK1MAP4K3 | |
| SCHEMBL31435912 | 0.87 | NTRK1 (0.36) | METGRK2GRK5PAK1 | |
| SCHEMBL31435990 | 0.85 | PTPN11 (0.39) | METGRK2GRK5PAK1MAP4K3 | |
| SCHEMBL31436018 | 0.84 | CHRM3 (0.34) | MET | |
| SCHEMBL31435900 | 0.84 | MAP4K3 (0.41) | METGRK2GRK5PAK1MAP4K3 | |
| SCHEMBL31435980 | 0.83 | MAP4K3 (0.38) | METGRK2GRK5PAK1MAP4K3 | |
| SCHEMBL31435969 | 0.83 | MAP4K3 (0.38) | METPAK1MAP4K3 | |
| SCHEMBL31436008 | 0.81 | NTRK1 (0.37) | METGRK2GRK5PAK1MAP4K3 | |
| SCHEMBL31436028 | 0.80 | NTRK1 (0.36) | METGRK2GRK5PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2025-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | TYRO3, TH, TYR | ELANE 3500/4885MET 1081/4885GRK2 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.